Blending Chemistry & Biology ADC Design: Exploring Rationale- Driven Development of ALX2004 to Maximise Clinical Differentiation

• Highlighting design and selection of novel Topo1 payload, paired with anti-EFGR antibody
• Presenting preclinical performance of ALX2004 including activity with improved bystander activity and stability versus deruxtecan ADCs
• Sharing rationale and design to maximise therapeutic window and overcome toxicity class challenges

Speakers:

Marija Vrljic

Vice President, Antibody Technologies

ALX Oncology Holdings Inc.